TY - JOUR AU - Maemondo, M. AU - Inoue, A. AU - Kobayashi, K. PY - 2010 DA - 2010// TI - Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR JO - N Engl J Med VL - 362 UR - https://doi.org/10.1056/NEJMoa0909530 DO - 10.1056/NEJMoa0909530 ID - Maemondo2010 ER - TY - JOUR AU - Mitsudomi, T. AU - Morita, S. AU - Yatabe, Y. PY - 2010 DA - 2010// TI - Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial JO - Lancet Oncol VL - 11 UR - https://doi.org/10.1016/S1470-2045(09)70364-X DO - 10.1016/S1470-2045(09)70364-X ID - Mitsudomi2010 ER - TY - JOUR AU - Mok, T. S. AU - Wu, Y. L. AU - Thongprasert, S. PY - 2009 DA - 2009// TI - Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma JO - N Engl J Med VL - 361 UR - https://doi.org/10.1056/NEJMoa0810699 DO - 10.1056/NEJMoa0810699 ID - Mok2009 ER - TY - JOUR AU - Rosell, R. AU - Carcereny, E. AU - Gervais, R. PY - 2012 DA - 2012// TI - Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial JO - Lancet Oncol VL - 13 UR - https://doi.org/10.1016/S1470-2045(11)70393-X DO - 10.1016/S1470-2045(11)70393-X ID - Rosell2012 ER - TY - JOUR AU - Sequist, L. V. AU - Yang, J. C. AU - Yamamoto, N. PY - 2013 DA - 2013// TI - Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations JO - J Clin Oncol VL - 31 UR - https://doi.org/10.1200/JCO.2012.44.2806 DO - 10.1200/JCO.2012.44.2806 ID - Sequist2013 ER - TY - JOUR AU - Shaw, A. T. AU - Kim, D. W. AU - Nakagawa, K. PY - 2013 DA - 2013// TI - Crizotinib versus chemotherapy in advanced ALK-positive lung cancer JO - N Engl J Med VL - 368 UR - https://doi.org/10.1056/NEJMoa1214886 DO - 10.1056/NEJMoa1214886 ID - Shaw2013 ER - TY - JOUR AU - Solomon, B. J. AU - Mok, T. AU - Kim, D. W. PY - 2014 DA - 2014// TI - First-line crizotinib versus chemotherapy in ALK-positive lung cancer JO - N Engl J Med VL - 371 UR - https://doi.org/10.1056/NEJMoa1408440 DO - 10.1056/NEJMoa1408440 ID - Solomon2014 ER - TY - JOUR AU - Pilotto, S. AU - Peretti, U. AU - Novello, S. PY - 2013 DA - 2013// TI - PROFILing non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine JO - Expert Opin Pharmacother VL - 14 UR - https://doi.org/10.1517/14656566.2013.778828 DO - 10.1517/14656566.2013.778828 ID - Pilotto2013 ER - TY - JOUR AU - Christensen, J. G. AU - Zou, H. Y. AU - Arango, M. E. PY - 2007 DA - 2007// TI - Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma JO - Mol Cancer Ther VL - 6 UR - https://doi.org/10.1158/1535-7163.MCT-07-0365 DO - 10.1158/1535-7163.MCT-07-0365 ID - Christensen2007 ER - TY - JOUR AU - Camidge, D. R. AU - Bang, Y. J. AU - Kwak, E. L. PY - 2012 DA - 2012// TI - Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study JO - Lancet Oncol VL - 13 UR - https://doi.org/10.1016/S1470-2045(12)70344-3 DO - 10.1016/S1470-2045(12)70344-3 ID - Camidge2012 ER - TY - JOUR AU - Crino, L. AU - Kim, D. AU - Riely, G. J. PY - 2011 DA - 2011// TI - Initial phase II results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE 1005 JO - ASCO Meeting Abstracts VL - 29 ID - Crino2011 ER - TY - JOUR AU - Felip, E. AU - Orlov, S. AU - Park, K. PY - 2015 DA - 2015// TI - ASCEND-3: A single-arm, open-label, multicenter phase II study of ceritinib in ALKi-naive adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC) JO - ASCO Meeting Abstracts VL - 33 ID - Felip2015 ER - TY - JOUR AU - Kim, D. W. AU - Mehra, R. AU - Tan, D. S. PY - 2016 DA - 2016// TI - Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial JO - Lancet Oncol VL - 17 UR - https://doi.org/10.1016/S1470-2045(15)00614-2 DO - 10.1016/S1470-2045(15)00614-2 ID - Kim2016 ER - TY - JOUR AU - Mok, T. AU - Spigel, D. AU - Felip, E. PY - 2015 DA - 2015// TI - ASCEND-2: A single-arm, open-label, multicenter phase II study of ceritinib in adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC) previously treated with chemotherapy and crizotinib (CRZ) JO - ASCO Meeting Abstracts VL - 33 ID - Mok2015 ER - TY - JOUR AU - Ou, S. H. AU - Ahn, J. S. AU - Petris, L. PY - 2016 DA - 2016// TI - Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study JO - J Clin Oncol VL - 34 UR - https://doi.org/10.1200/JCO.2015.63.9443 DO - 10.1200/JCO.2015.63.9443 ID - Ou2016 ER - TY - JOUR AU - Shaw, A. T. AU - Gandhi, L. AU - Gadgeel, S. PY - 2016 DA - 2016// TI - Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial JO - Lancet Oncol VL - 17 UR - https://doi.org/10.1016/S1470-2045(15)00488-X DO - 10.1016/S1470-2045(15)00488-X ID - Shaw2016 ER - TY - JOUR AU - Kim, D. -. W. AU - Tiseo, M. AU - Ahn, M. -. J. PY - 2016 DA - 2016// TI - Brigatinib (BRG) in patients (pts) with crizotinib (CRZ)-refractory ALK+ non-small cell lung cancer (NSCLC): First report of efficacy and safety from a pivotal randomized phase (ph) 2 trial (ALTA) JO - ASCO Meeting Abstracts VL - 34 ID - Kim2016 ER - TY - JOUR AU - Solomon, B. J. AU - Bauer, T. M. AU - Felip, E. PY - 2016 DA - 2016// TI - Safety and efficacy of lorlatinib (PF-06463922) from the dose-escalation component of a study in patients with advanced ALK+ or ROS1+ non-small cell lung cancer (NSCLC) JO - ASCO Meeting Abstracts VL - 34 ID - Solomon2016 ER - TY - JOUR AU - Nokihara, H. AU - Hida, T. AU - Kondo, M. PY - 2016 DA - 2016// TI - Alectinib (ALC) versus crizotinib (CRZ) in ALK-inhibitor naive ALK-positive non-small cell lung cancer (ALK+ NSCLC): Primary results from the J-ALEX study JO - ASCO Meeting Abstracts VL - 34 ID - Nokihara2016 ER - TY - JOUR AU - Sukov, W. R. AU - Hodge, J. C. AU - Lohse, C. M. PY - 2012 DA - 2012// TI - ALK alterations in adult renal cell carcinoma: frequency, clinicopathologic features and outcome in a large series of consecutively treated patients JO - Modern Pathol VL - 25 UR - https://doi.org/10.1038/modpathol.2012.107 DO - 10.1038/modpathol.2012.107 ID - Sukov2012 ER - TY - JOUR AU - Bavi, P. AU - Jehan, Z. AU - Bu, R. PY - 2013 DA - 2013// TI - ALK gene amplification is associated with poor prognosis in colorectal carcinoma JO - Br J Cancer VL - 109 UR - https://doi.org/10.1038/bjc.2013.641 DO - 10.1038/bjc.2013.641 ID - Bavi2013 ER - TY - JOUR AU - Pietrantonio, F. AU - Maggi, C. AU - Bartolomeo, M. PY - 2014 DA - 2014// TI - Gain of ALK gene copy number may predict lack of benefit from anti-EGFR treatment in patients with advanced colorectal cancer and RAS-RAF-PI3KCA wild-type status JO - PLoS One VL - 9 UR - https://doi.org/10.1371/journal.pone.0092147 DO - 10.1371/journal.pone.0092147 ID - Pietrantonio2014 ER - TY - JOUR AU - Jia, S. W. AU - Fu, S. AU - Wang, F. AU - Shao, Q. AU - Huang, H. B. AU - Shao, J. Y. PY - 2014 DA - 2014// TI - ALK gene copy number gain and its clinical significance in hepatocellular carcinoma JO - World J Gastroenterol VL - 20 UR - https://doi.org/10.3748/wjg.v20.i1.183 DO - 10.3748/wjg.v20.i1.183 ID - Jia2014 ER - TY - JOUR AU - Gaal, J. C. AU - Flucke, U. E. AU - Roeffen, M. H. PY - 2012 DA - 2012// TI - Anaplastic lymphoma kinase aberrations in rhabdomyosarcoma: clinical and prognostic implications JO - J Clin Oncol VL - 30 UR - https://doi.org/10.1200/JCO.2011.37.8588 DO - 10.1200/JCO.2011.37.8588 ID - Gaal2012 ER - TY - JOUR AU - Kim, M. H. AU - Lee, S. AU - Koo, J. S. PY - 2015 DA - 2015// TI - Anaplastic lymphoma kinase gene copy number gain in inflammatory breast cancer (IBC): prevalence, clinicopathologic features and prognostic implication JO - PLoS One VL - 10 UR - https://doi.org/10.1371/journal.pone.0120320 DO - 10.1371/journal.pone.0120320 ID - Kim2015 ER - TY - JOUR AU - Chen, Y. AU - Takita, J. AU - Choi, Y. L. PY - 2008 DA - 2008// TI - Oncogenic mutations of ALK kinase in neuroblastoma JO - Nature VL - 455 UR - https://doi.org/10.1038/nature07399 DO - 10.1038/nature07399 ID - Chen2008 ER - TY - JOUR AU - Wang, M. AU - Zhou, C. AU - Sun, Q. PY - 2013 DA - 2013// TI - ALK amplification and protein expression predict inferior prognosis in neuroblastomas JO - Exp Mol Pathol VL - 95 UR - https://doi.org/10.1016/j.yexmp.2013.06.002 DO - 10.1016/j.yexmp.2013.06.002 ID - Wang2013 ER - TY - BOOK AU - Travis, W. D. AU - Muller-Hermelink, H. -. K. AU - Harris, C. C. PY - 2004 DA - 2004// TI - Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart PB - IARC Press CY - Lyon ID - Travis2004 ER - TY - JOUR AU - Brunelli, M. AU - Bria, E. AU - Nottegar, A. PY - 2012 DA - 2012// TI - True 3q chromosomal amplification in squamous cell lung carcinoma by FISH and aCGH molecular analysis: impact on targeted drugs JO - PLoS One VL - 7 UR - https://doi.org/10.1371/journal.pone.0049689 DO - 10.1371/journal.pone.0049689 ID - Brunelli2012 ER - TY - JOUR AU - Salido, M. AU - Pijuan, L. AU - Martinez-Aviles, L. PY - 2011 DA - 2011// TI - Increased ALK gene copy number and amplification are frequent in non-small cell lung cancer JO - J Thorac Oncol VL - 6 UR - https://doi.org/10.1097/JTO.0b013e3181fb7cd6 DO - 10.1097/JTO.0b013e3181fb7cd6 ID - Salido2011 ER - TY - JOUR AU - Pelosi, G. AU - Gasparini, P. AU - Cavazza, A. PY - 2012 DA - 2012// TI - Multiparametric molecular characterization of pulmonary sarcomatoid carcinoma reveals a nonrandom amplification of anaplastic lymphoma kinase (ALK) gene JO - Lung Cancer VL - 77 UR - https://doi.org/10.1016/j.lungcan.2012.05.093 DO - 10.1016/j.lungcan.2012.05.093 ID - Pelosi2012 ER - TY - JOUR AU - Preusser, M. AU - Berghoff, A. S. AU - Ilhan-Mutlu, A. PY - 2013 DA - 2013// TI - ALK gene translocations and amplifications in brain metastases of non-small cell lung cancer JO - Lung Cancer VL - 80 UR - https://doi.org/10.1016/j.lungcan.2013.01.019 DO - 10.1016/j.lungcan.2013.01.019 ID - Preusser2013 ER - TY - JOUR AU - Camidge, D. R. AU - Skokan, M. AU - Kiatsimkul, P. PY - 2013 DA - 2013// TI - Native and rearranged ALK copy number and rearranged cell count in non-small cell lung cancer: implications for ALK inhibitor therapy JO - Cancer VL - 119 UR - https://doi.org/10.1002/cncr.28311 DO - 10.1002/cncr.28311 ID - Camidge2013 ER - TY - JOUR AU - Katayama, R. AU - Khan, T. M. AU - Benes, C. PY - 2011 DA - 2011// TI - Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK JO - Proc Natl Acad Sci U S A VL - 108 UR - https://doi.org/10.1073/pnas.1019559108 DO - 10.1073/pnas.1019559108 ID - Katayama2011 ER - TY - JOUR AU - Katayama, R. AU - Shaw, A. T. AU - Khan, T. M. PY - 2012 DA - 2012// TI - Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers JO - Sci Transl Med VL - 4 UR - https://doi.org/10.1126/scitranslmed.3003316 DO - 10.1126/scitranslmed.3003316 ID - Katayama2012 ER -